TCL.AU

13.52

-0.52%↓

BXB.AU

20.37

-1.07%↓

COL.AU

20.26

+2.22%↑

QAN.AU

8.59

-2.61%↓

CAR.AU

32.73

-1.24%↓

TCL.AU

13.52

-0.52%↓

BXB.AU

20.37

-1.07%↓

COL.AU

20.26

+2.22%↑

QAN.AU

8.59

-2.61%↓

CAR.AU

32.73

-1.24%↓

TCL.AU

13.52

-0.52%↓

BXB.AU

20.37

-1.07%↓

COL.AU

20.26

+2.22%↑

QAN.AU

8.59

-2.61%↓

CAR.AU

32.73

-1.24%↓

TCL.AU

13.52

-0.52%↓

BXB.AU

20.37

-1.07%↓

COL.AU

20.26

+2.22%↑

QAN.AU

8.59

-2.61%↓

CAR.AU

32.73

-1.24%↓

TCL.AU

13.52

-0.52%↓

BXB.AU

20.37

-1.07%↓

COL.AU

20.26

+2.22%↑

QAN.AU

8.59

-2.61%↓

CAR.AU

32.73

-1.24%↓

CSL Ltd

Затворен

СекторИндустриални

257.01 0.65

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

250.43

Максимум

257.24

Ключови измерители

By Trading Economics

Приходи

1.3B

2B

Продажби

1.5B

8.2B

P/E

Средно за сектора

28.972

33.198

EPS

1.831

Дивидентна доходност

1.7

Марж на печалбата

24.437

Служители

32,698

EBITDA

1.5B

3.2B

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+26.05% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

1.70%

2.54%

Следваща дата на дивидент

9.04.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-14B

121B

Предишно отваряне

256.36

Предишно затваряне

257.01

Настроения в новините

By Acuity

34%

66%

121 / 468 Класиране в Industrials

CSL Ltd Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.02.2025 г., 21:55 ч. UTC

Печалби

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business -- Update

10.02.2025 г., 21:34 ч. UTC

Печалби

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business

12.08.2024 г., 23:23 ч. UTC

Печалби

CSL Annual Profit Rises by 20% on Immunoglobulins Growth -- Update

12.08.2024 г., 22:49 ч. UTC

Печалби

CSL Annual Profit Rises by 20%, Forecasts Fiscal Year 2025 Underlying Earnings Growth

21.03.2025 г., 02:03 ч. UTC

Пазарно говорене

Severe U.S. Influenza Season Could Benefit CSL -- Market Talk

11.02.2025 г., 22:30 ч. UTC

Пазарно говорене

Flu Vaccines Proving Problematic for CSL -- Market Talk

10.02.2025 г., 21:40 ч. UTC

Печалби

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business -- Update

10.02.2025 г., 21:19 ч. UTC

Печалби

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business

10.02.2025 г., 21:13 ч. UTC

Печалби

CSL Reaffirms Guidance for FY 2025 Net Profit of US$3.2 Billion-US$3.3 Billion at Constant FX

10.02.2025 г., 21:12 ч. UTC

Печалби

CSL Interim Dividend US$1.30/Security

10.02.2025 г., 21:12 ч. UTC

Печалби

CSL 1H Revenue US$8.48 Billion, Up 5% on Year

10.02.2025 г., 21:11 ч. UTC

Печалби

CSL 1H Net Profit US$2.07 Billion, Up 3% on Year

7.11.2024 г., 03:53 ч. UTC

Пазарно говорене

U.S. Tariffs Could Force Moves by Australian Med-Techs -- Market Talk

22.10.2024 г., 22:53 ч. UTC

Пазарно говорене

CSL's R&D Update Seen as Neutral Overall -- Market Talk

10.10.2024 г., 22:20 ч. UTC

Пазарно говорене

CSL Bull Looking for Update on Gross Margin -- Market Talk

13.08.2024 г., 00:33 ч. UTC

Пазарно говорене

CSL Profit Outlook Looks Weaker Than Expected -- Market Talk

12.08.2024 г., 22:34 ч. UTC

Печалби

CSL Annual Profit Rises by 20%, Forecasts FY 2025 Underlying Earnings Growth

12.08.2024 г., 22:18 ч. UTC

Печалби

CSL Expects FY2025 Revenue Growth of Roughly 5%-7% at Constant Currency

12.08.2024 г., 22:18 ч. UTC

Печалби

CSL: Conditions for Seqirus Remain Challenging, But Unit Expected to Outperform Market

12.08.2024 г., 22:17 ч. UTC

Печалби

CSL: Has a Number of Efficiency Initiatives Underway in Plasma Collections, Manufacturing Operations

12.08.2024 г., 22:16 ч. UTC

Печалби

CSL: Momentum in Behring Seen Underpinned by Strong Patient Demand in Immunoglobulins

12.08.2024 г., 22:15 ч. UTC

Печалби

CSL: Remains Confident in Medium-Term Double-Digit Earnings Growth Target

12.08.2024 г., 22:14 ч. UTC

Печалби

CSL: Vifor Continues to Grow Iron Volume in Europe Despite Generic Entrants

12.08.2024 г., 22:13 ч. UTC

Печалби

CSL Expects FY2025 Underlying Profit Up Between 10%-13% on Constant Currency Basis

12.08.2024 г., 22:13 ч. UTC

Печалби

CSL Expects FY2025 Underlying Profit Between US$3.2 Billion-US$3.3 Billion

12.08.2024 г., 22:11 ч. UTC

Печалби

CSL: Outlook for Behring Positive But Competitive Pressures Increased Recently

12.08.2024 г., 22:10 ч. UTC

Печалби

CSL FY Underlying Profit Up 15% on Constant Currency Basis to US$3.01 Billion

12.08.2024 г., 22:09 ч. UTC

Печалби

CSL FY Revenue US$14.80 Billion, Up 11% On-Year

12.08.2024 г., 22:08 ч. UTC

Печалби

CSL FY Underlying Profit US$2.91 Billion, Up 11% On-Year

12.08.2024 г., 22:07 ч. UTC

Печалби

CSL FY Net Profit US$2.64 Billion, Up 20% On-Year

Сравнение с други в отрасъла

Ценова промяна

CSL Ltd Прогноза

Ценова цел

By TipRanks

26.05% нагоре

12-месечна прогноза

Среден 317.092 AUD  26.05%

Висок 360.3 AUD

Нисък 250 AUD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за CSL Ltd през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

12

Купи

2

Задържане

0

Продай

Настроение

By Acuity

121 / 468 Класиране в Индустриални

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно CSL Ltd

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.